Novavax, Inc. is a clinical-stage vaccine company headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is a public company that trades under the symbol "NVAX". In June 2013, Novavax acquired the Matrix-MTM adjuvant platform with the purchase of Swedish company Isconova AB. Novavax is developing a vaccine candidate for respiratory syncytial virus (RSV), which is being studied in older adults, infants via maternal immunization and pediatrics. There are currently no vaccines approved for RSV. Novavax announced positive top-line data from a Phase 2 clinical trial of its RSV-F vaccine in older adults. A Phase 3 clinical trial of the RSV-F vaccine for older adults was initiated in November 2015. In September 2016, Novavax announced that its RSV-F vaccine for lower respiratory tract disease did not meet its objectives in a clinical trial. The vaccine was well-tolerated by patients. But it did not demonstrate efficacy in preventing RSV-associated lower respiratory tract disease or reducing the occurrence of all symptomatic respiratory disease, according to a company statement. Companys stock collapsed more than 85% after the announcement.
Highest paying job titles at Novavax, Inc include Quality Control Manager, Senior Scientist, and Director of Life Sciences